A detailed history of Royal Bank Of Canada transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,321 shares of VERA stock, worth $226,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,321
Previous 4,583 16.1%
Holding current value
$226,674
Previous $165,000 42.42%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$34.09 - $46.71 $25,158 - $34,471
738 Added 16.1%
5,321 $235,000
Q2 2024

Aug 14, 2024

SELL
$33.72 - $48.82 $76,443 - $110,674
-2,267 Reduced 33.09%
4,583 $165,000
Q1 2024

Nov 05, 2024

BUY
$14.91 - $49.14 $33,800 - $111,400
2,267 Added 49.47%
6,850 $295,000
Q1 2024

May 15, 2024

SELL
$14.91 - $49.14 $58,745 - $193,611
-3,940 Reduced 36.52%
6,850 $295,000
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $48,298 - $83,184
5,199 Added 92.99%
10,790 $165,000
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $30,874 - $44,229
2,252 Added 67.45%
5,591 $76,000
Q2 2023

Aug 14, 2023

BUY
$6.11 - $17.83 $9,928 - $28,973
1,625 Added 94.81%
3,339 $53,000
Q1 2023

May 15, 2023

SELL
$5.41 - $18.3 $4,430 - $14,987
-819 Reduced 32.33%
1,714 $13,000
Q4 2022

Feb 14, 2023

BUY
$15.74 - $22.19 $29,307 - $41,317
1,862 Added 277.5%
2,533 $49,000
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $1,234 - $2,074
93 Added 16.09%
671 $15,000
Q2 2022

Aug 15, 2022

SELL
$12.82 - $23.4 $9,781 - $17,854
-763 Reduced 56.9%
578 $8,000
Q1 2022

May 16, 2022

SELL
$17.8 - $28.06 $24,119 - $38,021
-1,355 Reduced 50.26%
1,341 $32,000
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $28,759 - $68,592
1,916 Added 245.64%
2,696 $72,000
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $10,693 - $23,868
780 New
780 $13,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.15B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.